FDA Panel Backs Proposed Tofacitinib Dosing for Ulcerative Colitis

Share this post

Pfizer scored a win in its efforts to move forward a delayed application for new use of its rheumatoid arthritis drug for treating chronic inflammation of the colon.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply